QUICK LINKS
 
bullet Diagnostics
bullet Clinical Diagnostics
bullet Instant Check
bullet Cytoactiv
bullet Bionexia HCG-Combo
bullet Bionexia Strep A Ratio
bullet Bionexia ph-Balance
bullet Bionexia Streptokokken A
bullet Bionexia Streptokokken B
bullet Bionexia Hb/Hp Complex
bullet Bionexia FOBplus
bullet Bionexia Chlamydia Antigen
bullet Real Microbiology *NEW*
bullet Real Plant Diagnostic *NEW*
bullet SASperm *NEW*
bullet

Life Science

bullet

Antibodies

bullet Biological Enzyme Pyrolase
bullet Blot
bullet Cellkines
bullet Clinical Specimens
bullet Custom Panels
bullet Drug Discovery
bullet Elisa
bullet Microbiology & Biochemistry
bullet NATtrol
bullet Oxidative Stress
bullet Real Electrophoresis *NEW*
bullet Real Molecular Biology *NEW*
bullet Seroconversion Panels
bullet Support Reagents
bullet Viral Lysates
bullet Instrumentation
bullet  AUTOBLOT 3000

 
 
 
 

 

 

CYTOACTIV - Product's description

 

Home How does it work? Techincal specs Scientific references Ordering information FAQ

 

 

 

The prognostic marker for cervical dysplasia!

 

State of the Art

 

Human papilloma viruses (HPV) are playing a decisive role at the development of cervical cancer (carcinome). Therefore the easy and reliable detection (diagnosis) of HPV induced changes to the cells plays a vital role in cancer prevention.

 

The routinely performed cytologic exam by pap smear (Papanicolaou staining), including coloscopy, has played a central part in the continuous

reduction in the frequency of cervical carcinoma cases.

 

The L1 capsidprotein is a nuclear protein that is rapidly transported into the

nucleus of the cell after it is synthesised in the cytoplasm. Therefore the nuclear

staining is the specific staining. In addition to a strong nuclear staining sometimes

a vesicular staining within the cytoplasm is observed too (ribosomes producing the L1 Capsidprotein). (see picture 2a).

Thanks to these procedures, characteristic changes in the cell structure, like dysplasia, can be detected years before an invasive carzinome originates.

 

Most dysplasia cases do not need to be treated in the first place as about 80% of them regress spontaneously.

 

But as there are no morphological or molecularbiological criteria indicating if there will be remission to a healthy state or a progression towards cancer, the detection of dysplasia leads to a variety of confusion in the patients.

 

The results are often excessive therapies with a large amount of unnecessary surgery.

 

The new prognostic marker cytoactiv® provides now transparency and gives your patients the safe feeling to be in good hands.

 

It all depends on the immune system

 

Latest research proves that by detecting the L1capsidprotein you can predict the prognosis of adysplasia.

(Source: Griesser et al.; AQCH, Vol. 26, No. 5, Oct 04, p. 241-245)

 

These observations can be explained by the biological properties of the L1 capsidprotein that can be detected by cytoactiv®.

 

If cytoactiv® proves positive, a stimmulation of the immune system occurs resulting in a consecutive healing of the dysplasia.

 

If the L1-capsidprotein can not be detected and there is no consecutive stimulation of the immune system the dysplasia can develop into cancer.

 

 

Easy and reliable

 

Multiple applications

 

cytoactiv® is an immunochemical staining method, extremely simple and robust in its application.

 

The morphology of the cells remains intact by this method so that you can do the evaluation under the microscope as usual.

 

One positively stained cell - detected by its red nucleus - is sufficient for the positive result.

 

You can stain with the same staining protocol native smears, pap smears, and monolayer slides as well as histologic sections.

 

 

A list of your advantages

 

puce

The prognostic marker for cervical dysplasia

puce

Automizable staining and evaluation

puce

Simple, fast and reliable results within 90 minutes

puce

Can be processed in any cytologic laboratory without the need of sophisticated equipment

 

Our brochure in .pdf format is available for download here

 

 

Article number Description Content

Insert

SCA1950 Cytoactiv HPV L1 Screening Set
Immunochemical detection of the HPV L1 capsidprotein
50 tests

Instruction manual
.pdf

SCA0850 Cytoactiv HPV L1 high risk Set
Immunochemical detection of the HPV L1 capsidprotein of high risk types
50 tests

Instruction manual
.pdf

Accessories
Article number Description Content  
CAPZ5 HPV-Positive control 5 slides  
CAWP50 wash buffer concentrate 
20times concentrated
125 ml  
CAZP50 citric buffer concentrate
10tmes concentrated
150 ml  

 

 

 

CONTACT US:

 

HHC - Switzerland & Worldwide

sales@helveticahealthcare.com

Tel +41 (0)22 788 8812
Tel +41 (0)22 534 9454
Fax +41 (0) 22 594 8507

HHC - Deutschland

deutschland@helveticahealthcare.com

Tel +49 (0)89 2351 9958


HHC - Italia

italia@helveticahealthcare.com

Tel +39
3284516949

 

HHC - Mexico

mexico@helveticahealthcare.com


We accept credit cards!
 

 

 

NEWS

HHC is sponsoring The European Bio Alpine Convention
(3rd - 4th of December 2008, Geneva)

HHC is honored to be one of the sponsors of the European Bio Alpine Convention which is taking place on 3rd and 4th December 2008. Click here to download the program in pdf or here below to visit their website.
HHC TV is now available!

HHC is pleased to announce that a specific youtube page is now available. This page will be implemented in the next months and furnished with short movies presenting our products and relevant scientific news.
HHC TV link


sitemap - Copyright © 2007 - Helvetica Health Care Sàrl - Last update October 2008